These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23252557)

  • 1. From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
    Roukos DH; Papaloukas C; Tzaphlidou M
    Future Oncol; 2013 Jan; 9(1):5-8. PubMed ID: 23252557
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BRAF inhibitor and MEK inhibitor].
    Uhara H
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
    Chapman PB; Solit DB; Rosen N
    Cancer Cell; 2014 Nov; 26(5):603-4. PubMed ID: 25517746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
    Gutzmer R
    J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
    [No Abstract]   [Full Text] [Related]  

  • 8. Protein kinase inhibitors in melanoma.
    Eigentler TK; Meier F; Garbe C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2195-201. PubMed ID: 23992377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
    Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new standard of care for metastatic melanoma?
    Sharma SP
    Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
    [No Abstract]   [Full Text] [Related]  

  • 11. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.
    Queirolo P; Spagnolo F
    Cancer Metastasis Rev; 2017 Mar; 36(1):35-42. PubMed ID: 28299583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.
    Mai R; Zhou S; Zhong W; Rong S; Cong Z; Li Y; Xie Q; Chen H; Li X; Liu S; Cheng Y; Huang Y; Zhou Y; Zhang G
    Oncotarget; 2015 Sep; 6(29):28502-12. PubMed ID: 26143635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis.
    Zhao CY; Chou S; Liu RC; Fernandez-Peñas P
    Pigment Cell Melanoma Res; 2018 Mar; 31(2):341-344. PubMed ID: 29131505
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials.
    Liu M; Yang X; Liu J; Zhao B; Cai W; Li Y; Hu D
    Oncotarget; 2017 May; 8(19):32258-32269. PubMed ID: 28416755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Melanoma].
    Uhara H
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targets in melanoma: map kinase pathway.
    Haluska FG; Ibrahim N
    Curr Oncol Rep; 2006 Sep; 8(5):400-5. PubMed ID: 16901402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
    Smalley KS; Flaherty KT
    Br J Cancer; 2009 Feb; 100(3):431-5. PubMed ID: 19156138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Raf inhibitors.
    McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):633-48. PubMed ID: 19715444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review.
    Yu Q; Xie J; Li J; Lu Y; Liao L
    Cancer Med; 2019 Sep; 8(12):5414-5424. PubMed ID: 31393083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.